How to Buy Aprea Therapeutics Stock
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.
Aprea Therapeutics stock last closed at $4.15, down 3.71% from the previous day, and has decreased 72.86% in one year. It has underperformed other stocks in the Biotechnology industry by 0.4 percentage points. Aprea Therapeutics stock is currently +49.28% from its 52-week low of $2.78, and -75.23% from its 52-week high of $16.75.
There are currently 3.74M APRE shares outstanding. The market cap of APRE is $15.51M. In the last 24 hours, 7195 APRE shares were traded.
How to Buy Aprea Therapeutics Stock
Not sure how to invest in Aprea Therapeutics stock? Here's how.
- Decide where to buy Aprea Therapeutics stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you choose where to buy Aprea Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Select your method of payment and add your info.
- Evaluate Aprea Therapeutics stock: The Aprea Therapeutics ticker symbol is APRE. Is Aprea Therapeutics stock a good investment? Should you buy shares of APRE? How do APRE's underlying business fundamentals look? Do top analysts think Aprea Therapeutics is a good buy? Why has APRE's stock price moved recently? (Hint: Our stock research tools can help you decide if APRE is a good stock to buy).
- Make your APRE purchase: Decide if you will purchase APRE shares at the current market price or use a limit order to buy APRE shares at a particular price.
- Get notifications regarding your APRE investment: Create a watchlist to track your new investment in Aprea Therapeutics shares.
Step 1: Decide where to buy Aprea Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy APRE shares.
Our preferred brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Real Estate, New York to Shanghai — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected your brokerage, you need to fill out some personal info so you are able to buy APRE stock today.
How to Create a New Brokerage Account on eToro
- Click here to get started.
- Provide your personal details to start your new brokerage account.
- Send your information by pressing the "Create Account" button.
Step 3: Fund your brokerage account
Now that you have created your account on the best stock market app for beginners, you can securely and quickly fund your account:
Watch the tutorial below if you need help transferring money into your investment account.
Step 4: Evaluate Aprea Therapeutics stock
Once you have figured out the best place to buy Aprea Therapeutics stock, it's crucial to evaluate their stock before you invest, so you can wrap your head around the risk and opportunity.
Aprea Therapeutics shares data
Fundamentals of APRE
WallStreetZen was built to help average investors perform more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on APRE's stock page.
What is the fair value of APRE stock?
Analysts use many financial metrics, analyses, models, and charts to gauge APRE's intrinsic value.
Using relative valuations methods:
- APRE may be undervalued based on its P/E ratio of 0.38x, relative to Biotechnology industry P/E ratio of 12.89x
- APRE may be undervalued based on its P/B ratio of 0.66x, relative to Biotechnology industry P/B ratio of 5.11x
You can do more valuation research on APRE's stock here.
Is APRE a healthy company?
Positive Financial Indicators:
- APRE has cash burn of 16809179. It has sufficient cash and short-term investments to cover this for at least one year.
- APRE has $27.73M in cash and short term investments. This is enough to cover its annual cash burn of $16.81M.
- There are more short-term assets than short-term liabilities on the APRE balance sheet.
- APRE has a low debt to equity ratio of 0.17.
- There are more short-term assets than long-term liabilities on the APRE balance sheet.
Negative Financial Indicators:
- APRE profit margin has gone down from N/A to -5,649.4% in the past year.
Do analysts think it's a good time to buy Aprea Therapeutics stock
Out of 1 Wall Street analysts who monitor APRE, the consensus analyst rating on APRE is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Most Recent APRE Analyst Recommendations
Joseph Pantginis, a bottom 1% analyst from HC Wainwright & Co. reiterates APRE with a buy rating and maintains their APRE price target from $20.00 to $20.00, on Sep 13, 2023.
You can dive deeper into what analysts are forecasting on the Aprea Therapeutics stock forecast page.
Metrics for Advanced APRE Traders
APRE Performance Metrics
Last year, APRE earnings were -$14.11M. During the last 3 year, APRE's earnings have grown by -86.49% per year. This was slower than the Biotechnology industry average of 7.44%.
You can research APRE's earnings and revenue performance here.
Are APRE insiders buying or selling the stock?
In the last 12 months, insiders at APRE have bought more shares than they have sold.
Bernd R. Seizinger, Director of APRE, was the latest APRE insider to buy. They bought $22,192.75 worth of APRE shares on Jun 7, 2023.
Learn more about who owns APRE shares here.
Can I get consistent income from APRE stock?
No, Aprea Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about APRE
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your APRE purchase
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a given dollar amount limit, place a limit order.
Click the Open button and eToro will execute your order.
If you want additional help buying stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your APRE investment
Now that you own some APRE stock, you'll want to stay up-to-date on your new stock purchase.
Add APRE to a watchlist to get the latest updates about your APRE stock.
APRE Feed
How to Buy Stock in Aprea Therapeutics
To reiterate, here are the 6 steps for buying Aprea Therapeutics stock:
- Decide where to buy Aprea Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Evaluate Aprea Therapeutics stock
- Make your APRE purchase
- Get notifications regarding your APRE investment
If you require a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you want to keep an eye on your investment in Aprea Therapeutics, click below.
Other Articles You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.